Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials

J Eur Acad Dermatol Venereol. 2020 Jan;34(1):e21-e24. doi: 10.1111/jdv.15866. Epub 2019 Aug 30.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Cardiovascular Diseases / complications*
  • Humans
  • Placebos
  • Psoriasis / complications
  • Psoriasis / drug therapy*
  • Randomized Controlled Trials as Topic

Substances

  • Antibodies, Monoclonal, Humanized
  • Placebos
  • tildrakizumab